Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Reexamination Certificate
2007-05-15
2007-05-15
Habte, Kahsay (Department: 1624)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
C546S017000, C546S018000
Reexamination Certificate
active
11154083
ABSTRACT:
The present invention relates to 1,3,8-triara-spiro[4.5]decan-2-one compounds as monoamine receptor modulators; compositions comprising the same; methods of inhibiting an activity of a monoamine receptor with said compounds; methods of treating a disease condition associated with a monoamine receptor using said compounds; and methods for identifying a subject suitable for treatment using said compounds.
REFERENCES:
patent: 3983234 (1976-09-01), Sayers
patent: 4138492 (1979-02-01), Noverola et al.
patent: 4255432 (1981-03-01), Kluge et al.
patent: 4332804 (1982-06-01), Clark
patent: 4353900 (1982-10-01), Clark
patent: 4367232 (1983-01-01), Boix-Igleasias et al.
patent: 4853394 (1989-08-01), King et al.
patent: 5025013 (1991-06-01), Barreau et al.
patent: 5214055 (1993-05-01), Peglion et al.
patent: 5216165 (1993-06-01), Mobilio et al.
patent: 5461066 (1995-10-01), Gericke et al.
patent: 5595872 (1997-01-01), Wetterau, II et al.
patent: 5621010 (1997-04-01), Sueda et al.
patent: 5707798 (1998-01-01), Brann
patent: 5795894 (1998-08-01), Shue et al.
patent: 5869488 (1999-02-01), Shue et al.
patent: 5877173 (1999-03-01), Olney et al.
patent: 5912132 (1999-06-01), Brann
patent: 5955281 (1999-09-01), Brann
patent: 6107324 (2000-08-01), Behan et al.
patent: 6140509 (2000-10-01), Behan et al.
patent: 6150393 (2000-11-01), Behan et al.
patent: 6358698 (2002-03-01), Weiner et al.
patent: 6756393 (2004-06-01), Andersson et al.
patent: 6815458 (2004-11-01), Andersson et al.
patent: 6911452 (2005-06-01), Schlienger et al.
patent: 7022698 (2006-04-01), Hamied et al.
patent: 7041667 (2006-05-01), Armour et al.
patent: 2004/0006081 (2004-01-01), Burrows et al.
patent: 2004/0006089 (2004-01-01), Thurleau et al.
patent: 2004/0106600 (2004-06-01), Andersson et al.
patent: 2004/0213816 (2004-10-01), Weiner et al.
patent: 2005/0014757 (2005-01-01), Andersson et al.
patent: 2005/0148018 (2005-07-01), Weiner et al.
patent: 2005/0244862 (2005-11-01), Brann
patent: 2005/0256108 (2005-11-01), Schlienger
patent: 2006/0094758 (2006-05-01), Andersson et al.
patent: 2006/0106063 (2006-05-01), Thygesen et al.
patent: 2006/0111399 (2006-05-01), Thygesen et al.
patent: 2006/0194778 (2006-08-01), Andersson et al.
patent: 2006/0194834 (2006-08-01), Andersson et al.
patent: 2006/0199794 (2006-09-01), Schlienger
patent: 2006/0199818 (2006-09-01), Andersson et al.
patent: 2006/0199842 (2006-09-01), Weiner et al.
patent: 2006/0205710 (2006-09-01), Schlienger et al.
patent: 2006/0205722 (2006-09-01), Andersson et al.
patent: 2006/0205780 (2006-09-01), Thygesen et al.
patent: 2006/0205781 (2006-09-01), Thygesen et al.
patent: 984843 (1976-03-01), None
patent: 0005318 (1979-11-01), None
patent: 0061333 (1982-09-01), None
patent: 0379441 (1990-07-01), None
patent: 0548015 (1993-06-01), None
patent: 0 260 070 (1993-08-01), None
patent: 0625507 (1994-11-01), None
patent: 2802206 (2001-06-01), None
patent: 157325 (1998-03-01), None
patent: WO 94/27967 (1994-12-01), None
patent: WO 97/08166 (1997-03-01), None
patent: WO 97/11940 (1997-04-01), None
patent: WO 97/38665 (1997-10-01), None
patent: WO 97/38984 (1997-10-01), None
patent: WO 98/17646 (1997-10-01), None
patent: WO 98/11128 (1998-03-01), None
patent: WO 98/44921 (1998-10-01), None
patent: WO 98/50534 (1998-11-01), None
patent: WO 99/52927 (1999-10-01), None
patent: WO 00/23076 (2000-04-01), None
patent: WO 00/56335 (2000-09-01), None
patent: WO 00/59497 (2000-10-01), None
patent: WO 00/69810 (2000-11-01), None
patent: WO 01/44191 (2001-06-01), None
patent: WO 01/66521 (2001-09-01), None
patent: WO 01/87839 (2001-09-01), None
patent: WO 02/079186 (2002-10-01), None
patent: WO 03/057698 (2003-07-01), None
patent: WO 03/057698 (2003-07-01), None
patent: WO 03/062206 (2003-07-01), None
patent: WO 03/062206 (2003-07-01), None
patent: WO 03/070246 (2003-08-01), None
patent: WO 03/086400 (2003-10-01), None
patent: WO 2004/000808 (2003-12-01), None
patent: WO 2004/000808 (2003-12-01), None
patent: WO 2004/064738 (2004-08-01), None
patent: WO 2004/064738 (2004-08-01), None
patent: WO 2004/064753 (2004-08-01), None
patent: WO 2005/063254 (2005-07-01), None
patent: WO 2005/112927 (2005-12-01), None
patent: WO 2006/036874 (2006-04-01), None
patent: WO 2006/037043 (2006-04-01), None
Adell, et al. 2005. Strategies for producing faster acting antidepressants.Drug Discovery Today, 10(8):578-585.
Akin, et al. 2004. Decreased serotonin 5-HT2Areceptor-stimulated phosphoinositide signaling in fibroblasts from melancholic depressed patients.Neuropsychopharmacology, 29:2081-2087.
Blier, et al. 2005. Potential mechanisms of action of atypical antipsychotic medications in treatment-resistant depression and anxiety.J. Clin. Psychiatry, 66(suppl 8):30-40.
Clifton, et al. 1982. Arylethanolamines Derived from Salicyclamide with α- and β-Adrenoceptor Blocking Activities. Preparation of Labetalol, its Enantiomers, and Related Salicyclamides.J. Med.Chem., 25:670-679.
Gillman, P. K. 2005. Monoamine oxidase inhibitors, opioid analgesics and serotonin toxicity.British Journal of Anaesthesia, 95(4):434-441.
Kanayama, et al. 2005. New treatment of lumbar disc herniation involving 5-hydroxytryptamine2Areceptor inhibitor: A randomized controlled trial.J. Neurosurg: Spine, 2:441-446.
Marek, et al. 2003. Synergistic action of 5-HT2Aantagonists and selective serotonin reuptake inhibitors in neuropsychiatric disorders.Neuropsychopharmacology, 28:402-412.
Marek, et al. 2005. The selective 5-HT2Areceptor antagonist M100907 enhances antidepressant-like behavioral effects of the SSRI fluoxetine.Neuropsychopharmacology, 30:2205-2215.
Möhrle, et al. 1990. Sodium mercury edetate dehydrogenation of N-aliphatic substituted 1,2,3,6-tetrahydropyridine derivatives.Arch. Pharm.(Weinheim), 323:109-115.
Ogawa, et al. 2005. Effects of R-102444 and its active metabolite R-96544, selective 5-HT2Areceptor antagonists, on experimental acute and chronic pancreatitis: Additional evidence for possible involvement of 5-HT2Areceptors in the development of experimental pancreatitis.European Journal of Pharmacology, 521:156-163.
Patel, et al. 2004. The highly selective 5-hydroxytryptamine (5-HT)2Areceptor antagonist, EMD 281014, significantly increases swimming and decreases immobility in male congenital learned helpless rats in the forced swim test.Synapse, 52:73-75.
Pierce, et al. 1995. 5-hydroxytryptamine-induced synovial plasma extravasation is mediated via 5-hydroxytryptamine2A receptors on sympathetic efferent terminals.The Journal of Pharmacology and Experimental Therapeutics, 275(1):502-508.
Stryjer, et al. 2003. Treatment of neuroleptic-induced akathisia with the 5-HT2Aantagonist trazodone.Clinical Neuropharmacology, 26(3):137-141.
Office Action dated Sep. 14, 1998, from U.S. Appl. No. 08/965,947 filed Oct. 20, 1997, now U.S. Appl. No. 5,955,281.
Interview Summary dated Nov. 17, 1998, from U.S. Appl. No. 08/965,947 filed Oct. 20, 1997, now U.S. Appl. No. 5,955,281.
Notice of Allowance and Fee(s) Due and Notice of Allowability dated Nov. 20, 2001, from U.S. Appl. No. 09/413,626 filed Oct. 6, 1999, now U.S. Appl. No. 6,358,698.
Specification from U.S. Appl. No. 11/416,527 filed May 3, 2006.
Specification from U.S. Appl. No. 11/416,855 filed May 3, 2006.
Notice of Allowance and Fee(s) Due and Notice of Allowability dated Jul. 12, 2005, from U.S. Appl. No. 10/601,070 filed Jun. 20, 2003.
Notice of Allowance and Fee(s) Due and Notice of Allowability dated Mar. 29, 2006, from U.S. Appl. No. 10/601,070 filed Jun. 20, 2003.
Office Action dated Oct. 5, 2006, from U.S. Appl. No. 11/418,322 filed May 3, 2006.
Adam, et al. 1989. Effects of repeated ritanserin on middle-aged poor sleepers.Psychopharmacology, 99:219-221.
Alvisi, N. 1892. Sulla formazione di derivati pirazolici dalle dicloridrine e dalla tribromidrina della glicerina ordinaria,Gazz.-Chem. Ital.22:158-168.
Antilla, et al. 2001. Copper-catalyzed coupling of arylboronic acids and amines.Organic Letters, 3(13):2077-2079.
Antilla, et al. 2002. The copper-catalyzedN-arylation of indoles.J. Am. Chem. Soc., 124:11684-11688.
Artico, et al. 1992. Aromatic hydrazide
Acadia Pharmaceuticals Inc.
Habte Kahsay
LandOfFree
Spiroazacyclic compounds as monoamine receptor modulators does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Spiroazacyclic compounds as monoamine receptor modulators, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Spiroazacyclic compounds as monoamine receptor modulators will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3787623